An Undervalued Opportunity In Biopharmaceuticals
•OXiGENE is an emerging small biopharmaceutical company listed on the Nasdaq.
•Its lead drug candidate could have a profound impact on the biopharmaceutical industry, but more importantly, ovarian cancer patients.
•We believe the company is significantly undervalued, and shares could trade higher soon.
A few months ago, we established a long position in an emerging micro-cap called OXiGENE Inc. (OXGN). This company operates in the biopharmaceutical industry, has a $55 million market cap and is listed on the NASDAQ. The chief reason that we initiated a long position is that we believe OXiGENE's ovarian cancer drug, ZYBRESTAT, has shown enough potential in clinical trials to warrant a partnership or buyout by a major pharmaceutical company in the coming months. We are also encouraged by the $30 million investment in the company by Symphony Capital LLC, which was unveiled today through a Life Sciences Report interview with the firm's co-founder, Mark Kessel. The company's three pipeline developments are:
1. ZYBRESTAT Combination therapies for the treatment of ovarian cancer and anaplastic thyroid cancer (ATC)
http://seekingalpha.com/article/2108163 ... aceuticals
Enviado: 2/6/2014 23:00